Follow the Climb Bio, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1bn. The latest transaction was reported on 30 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Thomas Stephen Basil. Every trade is accessible without an account.
15
Insider Decl.
n/a
Thresholds
€21,264
1 ops.
Buy Volume
€596,976
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Climb Bio, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$22.57.
31Σ signal
Buys €21,264€596,976 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.